Summit Therapeutics Inc.

SMMT

Summit Therapeutics Inc.

SMMT

Insider Sentiment (TTM):

Last Purchase:2026-06-12Last Sale:-Shares Purchased (TTM):8,466,977Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:110,051,164Shares Outstanding:775,458,141Institutional Ownership Pct.:14.19%

Earnings Market Reaction:

Filing Date:2026-07-23Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	419	107	225	239	298	212	105	94	28	61	71	24
Restricted Cash Current	0	0	0	0	0	0	0	0	0	0	0	0
Accounts Receivable Net Current	-	-	-	-	-	-	-	-	-	-	0	0
Short Term Investments	271	492	488	0	0	150	307	393	297	95	115	175
Prepaid Expense And Other Assets Current	30	18	7	8	11	9	11	2	2	5	3	-
Prepaid Expense Current	-	-	-	-	-	-	-	-	-	-	2	5
Assets Current	721	617	720	246	309	371	424	490	329	163	190	205
Other Assets Current	-	-	-	-	-	-	-	-	-	-	0	0
Assets Noncurrent
Property Plant And Equipment Net	2	2	1	1	1	1	0	0	0	0	0	0
Operating Lease Right Of Use Asset	19	19	21	5	6	6	7	8	9	9	6	6
Goodwill	2	2	2	2	2	2	2	2	2	2	2	2
Other Assets Noncurrent	8	8	7	7	7	4	3	2	2	2	4	4
Assets	752	648	751	262	324	384	436	503	342	177	203	218
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	23	28	20	22	23	5	5	3	3	6	3	3
Accrued Liabilities Current	65	44	32	27	26	21	20	18	12	7	9	4
Employee Related Liabilities Current	9	7	15	11	7	4	12	8	5	6	5	4
Operating Lease Liability Current	4	3	3	3	3	4	4	4	4	4	3	3
Other Liabilities Current	3	1	2	2	1	1	2	1	1	1	1	0
Notes Payable Current	-	-	-	-	-	-	-	25	100	-	0	100
Liabilities Current	104	83	73	65	60	35	42	59	140	23	20	114
Liabilities Noncurrent
Operating Lease Liability Noncurrent	17	17	18	3	2	3	3	4	5	6	3	4
Other Liabilities Noncurrent	2	2	2	2	2	2	2	2	2	3	2	1
Liabilities	122	102	92	69	65	39	47	65	147	133	125	119
Stockholders Equity
Long Term Notes Payable	-	-	-	-	-	-	0	0	0	100	100	0
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	8	8	8	7	7	7	7	7	7	7	7	7
Additional Paid In Capital	3,324	3,024	2,948	2,263	2,098	1,617	1,598	1,586	1,287	1,076	1,066	1,051
Accumulated Other Comprehensive Income Loss Net Of…	-3	-3	-3	-3	-3	-3	-2	-2	-2	-2	-2	-2
Retained Earnings Accumulated Deficit	-2,699	-2,484	-2,294	-2,075	-1,843	-1,277	-1,215	-1,153	-1,097	-1,037	-993	-957
Stockholders Equity	630	546	659	192	259	344	389	438	195	44	78	99
Liabilities And Stockholders Equity	752	648	751	262	324	384	436	503	342	177	203	218
Preferred Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Preferred Stock Shares Authorized	20	20	20	20	20	20	20	20	20	20	20	20
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Common Stock Shares Authorized	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000	1,000
Common Stock Shares Issued	793	776	775	744	743	742	738	737	724	702	702	698
Shares Outstanding	793	776	775	744	743	742	738	737	724	702	702	698

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-22.55%	-35.93%	-35.65%	-	-	-	-	-	-	-	-	-
2025	4.78%	-16.66%	6.20%	-8.04%	-24.14%	-33.06%	-10.01%	-12.30%	-1.77%	-3.60%	56.31%	4.85%
2024	-28.09%	68.72%	86.91%	36.06%	118.92%	122.85%	1.88%	-4.18%	2.04%	4.83%	30.63%	26.70%
2023	-	-	-	-15.98%	-3.61%	-6.70%	11.23%	36.29%	102.61%	23.53%	-2.01%	24.33%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	6.96	7.41	9.87	3.80	5.13	10.63	10.15	8.31	2.35	6.97	9.30	1.80
Quick Ratio	6.67	7.19	9.78	3.68	4.94	10.37	9.89	8.27	2.33	6.74	9.18	1.76
Working Capital	617.01M	533.33M	647.31M	181.54M	248.92M	335.87M	382.02M	431.28M	188.63M	139.83M	169.31M	91.21M
Leverage & Debt
Debt to Equity	0.19	0.19	0.14	0.36	0.25	0.11	0.12	0.15	0.75	3.00	1.61	1.20
Interest Coverage TTM	-	-	-	-102,892.00	-305.57	-44.30	-26.02	-22.66	-25.50	-36.81	-	-
Debt Ratio	0.16	0.16	0.12	0.27	0.20	0.10	0.11	0.13	0.43	0.75	0.62	0.55
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-1.10	-1.56	-1.44	-1.24	-1.00	-0.33	-0.31	-0.27	-0.23	-0.17	-0.99	-0.86
Free Cash Flow Per Share TTM	-0.59	-0.50	-0.43	-0.36	-0.28	-0.24	-0.20	-0.16	-0.14	-0.13	-0.12	-0.07
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-	-	-	-	-	-100.00%	-100.00%	-100.00%	-100.00%
Net Income Growth (1Y)	14.75%	400.96%	387.81%	368.59%	361.42%	107.50%	-64.01%	-67.09%	-72.95%	-80.65%	680.54%	589.64%
EPS Growth (1Y)	9.50%	376.81%	368.78%	358.03%	339.85%	97.30%	-68.96%	-68.40%	-73.34%	-89.58%	143.54%	106.49%
Valuation Metrics
P/E TTM	-13.24	-12.19	-12.11	-16.67	-21.18	-59.14	-57.94	-80.91	-34.15	-25.04	-2.63	-2.18
P/B TTM	18.00	26.93	19.85	79.89	60.91	41.35	32.98	36.34	28.31	65.72	20.82	13.13
Market Cap	11.34B	14.70B	13.08B	15.36B	15.80B	14.24B	12.82B	15.91B	5.52B	2.91B	1.62B	1.30B
Enterprise Value	10.92B	14.60B	12.85B	15.12B	15.50B	14.03B	12.72B	15.84B	5.59B	2.94B	1.65B	1.38B
Calculated Values
Free Cash Flow TTM	-459.82M	-384.53M	-323.59M	-270.17M	-207.38M	-173.70M	-142.25M	-113.02M	-97.61M	-93.84M	-76.89M	-52.25M
Net Debt	-419.68M	-106.83M	-225.58M	-238.88M	-297.87M	-211.84M	-105.19M	-69.60M	71.25M	38.39M	28.58M	76.21M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-12Purchase

Owner: Zanganeh, Mahkam

Title: Co-Chief Executive Officer

Shares: 3,810,000

Price/Share: $13.12

Value: $49,987,200.00

Shares Owned: 573,883,879

Relationship: Director,Officer,TenPercentOwner

Ownership: Indirect

2026-06-12Purchase

Owner: Duggan, Robert W

Title: Co-Chief Executive Officer

Shares: 3,810,000

Price/Share: $13.12

Value: $49,987,200.00

Shares Owned: 573,883,879

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

2026-06-04Purchase

Owner: Soni, Manmeet Singh

Title: COO and CFO

Shares: 50,000

Price/Share: $14.44

Value: $722,000.00

Shares Owned: 3,123,603

Relationship: Director,Officer

Ownership: Direct

2026-06-04Purchase

Owner: Zanganeh, Mahkam

Title: Co-Chief Executive Officer

Shares: 100,000

Price/Share: $14.60

Value: $1,460,000.00

Shares Owned: 25,824,474

Relationship: Director,Officer,TenPercentOwner

Ownership: Indirect

2026-06-04Purchase

Owner: Duggan, Robert W

Title: Co-Chief Executive Officer

Shares: 100,000

Price/Share: $14.60

Value: $1,460,000.00

Shares Owned: 25,824,474

Relationship: Director,Officer,TenPercentOwner

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-12	Zanganeh, Mahkam	Director,Officer,TenPercentOwner	Co-Chief Executive Officer	Indirect	Purchase	3,810,000	13.12	$49,987,200.00	573,883,879	4
2026-06-12	Duggan, Robert W	Director,Officer,TenPercentOwner	Co-Chief Executive Officer	Direct	Purchase	3,810,000	13.12	$49,987,200.00	573,883,879	4
2026-06-04	Soni, Manmeet Singh	Director,Officer	COO and CFO	Direct	Purchase	50,000	14.44	$722,000.00	3,123,603	4
2026-06-04	Zanganeh, Mahkam	Director,Officer,TenPercentOwner	Co-Chief Executive Officer	Indirect	Purchase	100,000	14.60	$1,460,000.00	25,824,474	4
2026-06-04	Duggan, Robert W	Director,Officer,TenPercentOwner	Co-Chief Executive Officer	Indirect	Purchase	100,000	14.60	$1,460,000.00	25,824,474	4
2025-10-21	Xia, Yu	Director	-	Indirect	Purchase	533,617	18.74	$9,999,982.58	32,057,147	4
2025-10-21	Zanganeh, Mahkam	Director,Officer,TenPercentOwner	Co-Chief Executive Officer	Indirect	Purchase	26,680	18.74	$499,983.20	76,680	4
2025-10-21	Duggan, Robert W	Director,Officer,TenPercentOwner	Co-Chief Executive Officer	Indirect	Purchase	26,680	18.74	$499,983.20	76,680	4
2025-09-11	Zanganeh, Mahkam	Director,Officer,TenPercentOwner	Co-Chief Executive Officer	Indirect	Purchase	5,000	18.07	$90,350.00	556,093,090	4
2025-09-11	Duggan, Robert W	Director,Officer,TenPercentOwner	Co-Chief Executive Officer	Direct	Purchase	5,000	18.07	$90,350.00	556,093,090	4
2024-03-27	Zanganeh, Mahkam	Director,Officer	Chief Executive Officer	Direct	Purchase	26,000	3.72	$96,720.00	520,814	4
2024-03-26	Dhingra, Ankur	Officer	Chief Financial Officer	Indirect	Purchase	100,000	3.75	$375,000.00	354,958	4
2023-12-13	Dhingra, Ankur	Officer	Chief Financial Officer	Indirect	Purchase	20,400	2.16	$44,064.00	254,958	4
2023-12-12	Zanganeh, Mahkam	Director,Officer	Chief Executive Officer	Direct	Purchase	5,000	2.07	$10,350.00	494,814	4
2023-10-13	Soni, Manmeet Singh	Director,Officer	Chief Operating Officer	Direct	Purchase	2,976,190	1.68	$4,999,999.20	2,976,190	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

14.19%

Inst. Shares: 110,051,164

Shares Outstanding: 775,458,141

2025-12-31

14.40%

Inst. Shares: 107,693,867

Shares Outstanding: 747,702,265

2025-09-30

13.12%

Inst. Shares: 97,517,461

Shares Outstanding: 743,415,917

2025-06-30

12.50%

Inst. Shares: 92,793,715

Shares Outstanding: 742,615,007

2025-03-31

12.27%

Inst. Shares: 90,590,346

Shares Outstanding: 738,076,003

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	110,051,164	775,458,141	14.19%
2025-12-31	107,693,867	747,702,265	14.40%
2025-09-30	97,517,461	743,415,917	13.12%
2025-06-30	92,793,715	742,615,007	12.50%
2025-03-31	90,590,346	738,076,003	12.27%
2024-12-31	85,263,700	718,541,896	11.87%
2024-09-30	78,530,322	726,656,045	10.81%
2024-06-30	69,357,526	707,904,643	9.80%
2024-03-31	48,780,312	701,785,250	6.95%
2023-12-31	31,619,436	619,646,180	5.10%
2023-09-30	31,542,031	697,739,477	4.52%
2023-06-30	34,160,600	697,685,365	4.90%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Summit Therapeutics Inc. (SMMT) — SEC Financial Statements & Analysis

Summit Therapeutics Inc. (SMMT) is a pharmaceutical preparations company. Summit Therapeutics Inc. trades on Nasdaq as: SMMT. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Summit Therapeutics Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.19x, a Price-to-Book (P/B) ratio of 18.00x (TTM), at a market cap of $11.34B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.19x
P/B TTM: 18.00x
Market Cap: $11.34B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Summit Therapeutics Inc. in?

Summit Therapeutics Inc. (SMMT) operates in the Pharmaceutical Preparations industry.

What is SMMT's market cap?

Summit Therapeutics Inc. (SMMT) has a market capitalization of $11.34B as of 2026-06-30.

What exchange does SMMT trade on?

Summit Therapeutics Inc. (SMMT) trades on the Nasdaq.